Innovent Biologics revenue and financials

1801 · HKEX · HKD

$83.90Change from previous close: −1.00%Absolute change: −$0.85

Close · November 16, 2026

In the fiscal year ended December 2025, Innovent Biologics reported revenue of ¥13.04B (+38.42% year over year). Net income was ¥813.57M, a net margin of 6.2%.

Annual revenue · 2025: ¥13.04B
  1. ¥28.77M2016
  2. ¥74.96M2017
  3. ¥9.48M2018
  4. ¥1.05B2019
  5. ¥3.84B2020
  6. ¥4.27B2021
  7. ¥4.56B2022
  8. ¥6.21B2023
  9. ¥9.42B2024
  10. ¥13.04B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+38.42%
2025 vs 2024
Net margin
6.2%
2024: -1.0%

How Innovent Biologics is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of CNY; per-share values in CNY; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue13,0429,4226,2064,5564,2703,8441,0489.575.028.8
Cost of revenue3,0442,2581,8071,3821,224772625———
Gross profit9,9987,1634,3993,1753,0453,0724239.575.028.8
Selling, general and administrative6,6405,0853,8513,4263,4261,77894835687.857.4
Research and development2,6242,2022,1122,8712,3231,8511,2951,222612385
Operating income734-123-1,564-3,123-2,703-557-1,820-1,569-625-413
EBIT734-123-1,564-3,123-2,703-557-1,820-1,569-625-413
EBITDA1,310263-1,288-2,878-2,538-489-1,746-1,506-565-360
Interest expense79.667.698.610262.568.459.569.057.253.8
Pre-tax income839-78.6-1,144-2,170-2,642-859-1,720-5,873-716-544
Income tax25.416.0-1168.887.0140————
Net income814-94.6-1,028-2,179-2,729-998-1,720-5,771-562-504
Net income to common shareholders814-94.6-1,028-2,179-2,729-998-1,720-5,771-562-504
Basic EPS0.48-0.06-0.66-1.46-1.87-0.74-1.46-17.24-5.96-6.57
Diluted EPS0.47-0.06-0.66-1.46-1.88-0.74-1.46-17.24-5.96-6.57
Average shares (basic)1,6771,6271,5601,4901,4561,3571,17833594.376.8
Average shares (diluted)1,7411,6271,5601,4901,4561,3571,17833594.376.8

Companies in the group: same industry, similar size